Byhealth Co., Ltd (SHE:300146)
China · Delayed Price · Currency is CNY 11.37
-0.21 (-1.81%)
At close: Mar 20, 2026
Byhealth Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 6,265 | 6,781 | 9,373 | 7,828 | 7,375 |
Other Revenue | - | 57.66 | 34.02 | 33.04 | 55.92 |
| 6,265 | 6,838 | 9,407 | 7,861 | 7,431 | |
Revenue Growth (YoY) | -8.38% | -27.30% | 19.66% | 5.79% | 21.93% |
Cost of Revenue | 2,011 | 2,321 | 2,938 | 2,506 | 2,544 |
Gross Profit | 4,254 | 4,518 | 6,468 | 5,356 | 4,887 |
Selling, General & Admin | 3,188 | 3,589 | 4,353 | 3,560 | 2,863 |
Research & Development | 88.95 | 148.63 | 179.33 | 158.5 | 150.3 |
Other Operating Expenses | 53.8 | 38.43 | 91.4 | 74.29 | 72.11 |
Operating Expenses | 3,331 | 3,774 | 4,622 | 3,795 | 3,091 |
Operating Income | 923.35 | 744.04 | 1,847 | 1,561 | 1,797 |
Interest Expense | - | -12.15 | -4.15 | -2.2 | -10.18 |
Interest & Investment Income | - | 57.73 | 159.89 | 231.76 | 167.18 |
Currency Exchange Gain (Loss) | - | 5.22 | -5.07 | -1.7 | -4.8 |
Other Non Operating Income (Expenses) | 43.39 | -1 | -4.18 | -2.51 | -2.97 |
EBT Excluding Unusual Items | 966.74 | 793.83 | 1,993 | 1,786 | 1,946 |
Gain (Loss) on Sale of Investments | 66.91 | 4.6 | 51.21 | -177.85 | 69.03 |
Gain (Loss) on Sale of Assets | 29.24 | 14.44 | 0.11 | -3.91 | 0.12 |
Asset Writedown | -54.47 | -4.5 | -1.41 | -8.87 | -1.2 |
Other Unusual Items | - | 92.23 | 152.9 | 109.12 | 164.32 |
Pretax Income | 1,008 | 900.61 | 2,196 | 1,705 | 2,178 |
Income Tax Expense | 191.87 | 252.75 | 417.18 | 293.53 | 411.7 |
Earnings From Continuing Operations | 816.55 | 647.86 | 1,779 | 1,411 | 1,766 |
Minority Interest in Earnings | -34.4 | 4.97 | -32.44 | -25.41 | -12.32 |
Net Income | 782.15 | 652.83 | 1,746 | 1,386 | 1,754 |
Net Income to Common | 782.15 | 652.83 | 1,746 | 1,386 | 1,754 |
Net Income Growth | 19.81% | -62.62% | 26.01% | -20.99% | 15.07% |
Shares Outstanding (Basic) | 1,664 | 1,674 | 1,695 | 1,690 | 1,655 |
Shares Outstanding (Diluted) | 1,664 | 1,718 | 1,695 | 1,711 | 1,670 |
Shares Change (YoY) | -3.13% | 1.33% | -0.91% | 2.42% | 5.21% |
EPS (Basic) | 0.47 | 0.39 | 1.03 | 0.82 | 1.06 |
EPS (Diluted) | 0.47 | 0.38 | 1.03 | 0.81 | 1.05 |
EPS Growth | 23.68% | -63.11% | 27.16% | -22.86% | 9.38% |
Free Cash Flow | 1,080 | 380.19 | 794.08 | 1,134 | 1,556 |
Free Cash Flow Per Share | 0.65 | 0.22 | 0.47 | 0.66 | 0.93 |
Dividend Per Share | - | 0.360 | 0.900 | 0.180 | 0.700 |
Dividend Growth | - | -60.00% | 400.00% | -74.29% | - |
Gross Margin | 67.90% | 66.06% | 68.76% | 68.13% | 65.76% |
Operating Margin | 14.74% | 10.88% | 19.63% | 19.86% | 24.18% |
Profit Margin | 12.48% | 9.55% | 18.56% | 17.63% | 23.60% |
Free Cash Flow Margin | 17.24% | 5.56% | 8.44% | 14.43% | 20.94% |
EBITDA | 1,213 | 964.15 | 2,072 | 1,773 | 2,012 |
EBITDA Margin | 19.35% | 14.10% | 22.02% | 22.55% | 27.07% |
D&A For EBITDA | 289.2 | 220.11 | 224.91 | 212.18 | 215.35 |
EBIT | 923.35 | 744.04 | 1,847 | 1,561 | 1,797 |
EBIT Margin | 14.74% | 10.88% | 19.63% | 19.86% | 24.18% |
Effective Tax Rate | 19.03% | 28.06% | 19.00% | 17.22% | 18.90% |
Revenue as Reported | - | 6,838 | 9,407 | 7,861 | 7,431 |
Advertising Expenses | - | 758.7 | 1,113 | 996.14 | 778.63 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.